Patients with advanced cancer have high rates of psychological distress, including depression, anxiety, and spiritual despair. This study examined the effectiveness of individual meaning-centered psychotherapy (IMCP) in comparison with supportive psychotherapy (SP) and enhanced usual care (EUC) in improving spiritual well-being and quality of life and reducing psychological distress in patients with advanced cancer. METHODS: Patients (n 5 321) were randomly assigned to IMCP (n 5 109), SP (n 5 108), or EUC (n 5 104). Assessments were conducted at 4 time points: before intervention, midtreatment (4 weeks), 8 weeks after treatment, and 16 weeks after treatment. RESULTS: Significant treatment effects (small to medium in magnitude) were observed for IMCP, in comparison with EUC, for 5 of 7 outcome variables (quality of life, sense of meaning, spiritual well-being, anxiety, and desire for hastened death), with Cohen's d ranging from 0.1 to 0.34; no significant improvement was observed for patients receiving SP (d < 0.15 and P >.05 for all variables). The effect of IMCP was significantly greater than the effect of SP for quality of life and sense of meaning (d 5 0.19) but not for the remaining study variables. CONCLUSIONS: This study provides further support for the efficacy of IMCP as a treatment for psychological and existential/spiritual distress in patients with advanced cancer. Significant treatment effects (small to moderate effect sizes) were observed in comparison with usual care, and somewhat more modest differences in improvement (small effect sizes) were observed in comparison with SP. Thus, the benefits of meaning-centered psychotherapy appear to be unique to the intervention and highlight the importance of addressing existential issues with patients approaching the end of life. Cancer
INTRODUCTION
The past decade has witnessed growing interest in the development of psychotherapeutic interventions that incorporate aspects of spirituality and, in particular, a sense of meaning. This approach is particularly appealing to patients with advanced cancer, for whom concerns about death and dying may engender spiritual and existential distress. [1] [2] [3] A number of interventions focusing on spiritual well-being were developed in the 1980s and 1990s, but these studies rarely targeted patients with advanced or terminal illness. [4] [5] [6] More recently, interest in spiritual well-being has prompted a new wave of interventions that directly target this population. For example, Managing Cancer and Living Meaningfully (CALM) is a 3-to 8-session intervention grounded in "relational, attachment and existential theory" (p 236). 7 A pilot study of CALM provided some support for this intervention, but only 24 of 50 patients completed the treatment, and only 16 patients completed a follow-up assessment. Thus, although further research may demonstrate the effectiveness of this intervention, there is currently little evidence to support its utility. Similarly, Chochinov et al 8 developed dignity therapy, which helps end-stage cancer patients to create a legacy document for their loved ones. Their randomized clinical trial of dignity therapy demonstrated little evidence of significant improvement between pre-and postintervention levels of distress, spiritual well-being, or quality of life. Ando et al 9 also used a short-term life review intervention to enhance spiritual well-being in terminally ill cancer patients. Their study of 68 palliative care patients demonstrated significantly greater improvement (in comparison with patients assigned to a control group) on a measure of spiritual well-being as well as several items drawn from a measure of psychological distress. Despite these advances, none of these interventions have demonstrated strong treatment effects in large, systematic clinical trials.
In response to the need for an intervention with demonstrated effectiveness in alleviating the existential distress (ie, spiritual despair and loss of meaning) that often arises in patients with advanced disease, we developed meaning-centered psychotherapy (MCP). This intervention differs from other end-of-life interventions by focusing squarely on identifying sources of meaning in the patient's life, whereas other interventions focus on meaning indirectly by, for example, reviewing the patient's personal history (eg, legacy). This intervention is based on the underlying belief that existential distress is grounded in the belief that one's life is meaningless 10 ; MCP addresses existential distress by helping patients to sustain or enhance their sense of meaning by reexperiencing and recreating meaning with the sources of meaning described in Frankl's seminal book, Man's Search for Meaning.
11 MCP was originally designed as a groupbased intervention, and 2 randomized controlled trials demonstrated significantly greater improvement with MCP for a range of outcomes in comparison with supportive group psychotherapy. 12, 13 Since that time, researchers around the globe have adopted MCP, with pilot studies and culturally sensitive adaptations arising in multiple countries and settings. [14] [15] [16] [17] [18] However, a groupbased intervention can be problematic when it is applied to patients with advanced disease (eg, worsening illness and medical appointments often interfere with scheduled group sessions), and this highlights the need for an individualized approach.
We developed and tested an individualized version of MCP (individual meaning-centered psychotherapy [IMCP]), which showed strong, albeit preliminary results in a small pilot study. 19 Significant improvements were observed for most outcome variables in comparison with patients receiving an attention-control condition (therapeutic massage). However, this control condition prevented an analysis of whether IMCP provides unique benefits in comparison with other psychotherapeutic approaches commonly used in medical settings, such as supportive psychotherapy (SP). Indeed, multiple studies have demonstrated improvements in patient outcomes after SP, and this intervention is widely used in oncology settings. 20 The current study provides a rigorous test of IMCP in a large sample of patients with advanced cancer. We hypothesized that IMCP would result in significantly greater improvements in our primary outcomesspiritual well-being, a sense of meaning, and quality of life-in comparison with SP and enhanced usual care (EUC).
MATERIALS AND METHODS

Participants
Patients with advanced cancer were recruited from outpatient clinics at Memorial Sloan Kettering Cancer Center between March 2011 and March 2016. Power calculations indicated that a sample size of 104 participants per treatment arm (n 5 312) was required to generate a power of .80 for detecting a time 3 treatment interaction effect of d 5 0.20. Prospective participants were identified through flyers posted in the ambulatory care clinics, via solicitation by research assistants, and through referrals from treating physicians. The eligibility requirements were as follows: the patient had to be at least 18 years old and English-speaking, have a stage IV solid tumor cancer, and have at least moderate distress (a Distress Thermometer score of 4 or higher 21 ). Patients with significant cognitive impairment or severe psychiatric disturbance (eg, psychosis or suicidal ideation) according to a clinician's assessment were excluded. All participants provided written informed consent.
A total of 4618 patients were assessed for eligibility, and 346 were deemed eligible and provided informed consent (see Fig. 1 ). Of these 346 participants, 25 were used as training cases to train staff in the provision of IMCP or SP. The remaining 321 individuals were randomized to 1 of the 3 treatment arms (IMCP [n 5 109], SP [n 5 108], or EUC [n 5 104]). Randomization was stratified according to the pretreatment level of distress (Distress Thermometer scores of 4-6 vs 7-10) and physical functioning (Karnofsky performance rating scale scores of 60-79 vs 80-100) 22 . Because the study involved a psychotherapy intervention, neither patients nor therapists were blind to the treatment arm. The final sample, described in Table 1 Fig. 1 ). There was no significant difference between IMCP and SP in the average number of sessions attended (5.3 vs 4.9; t 5 0.97; P 5 .33) or in the proportion that completed all 7 sessions (70.6% vs 63.0%; v 2 5 1.23; P 5 .27). Of the 321 participants, 220 
Procedures
Participants were administered a battery of questionnaires before the first session. There were 3 primary outcome variables used to measure existential distress and overall quality of life: the Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (SWB), 23 the Personal Meaning Index of the Life Attitude ProfileRevised (LAP-R), 24 and the McGill Quality of Life Questionnaire (MQOL). 25 The secondary outcome variables, measuring psychological distress more generally, were the Hopelessness Assessment in Illness (HAI) questionnaire, 26 the Schedule of Attitudes Toward Hastened Death (SAHD), 27 and the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and Hospital Anxiety and Depression Scale-Depression (HADS-D) scales. 28 Participants also completed a pretreatment questionnaire (before randomization) that elicited their preferences for psychotherapy content and awareness of their prognosis. Outcome variables were re-administered along with a measure of therapeutic alliance (the Working Alliance Inventory Short Form 29 ) for patients randomized to MCP or SP before the fourth treatment session (1 month after randomization for the EUC condition). Outcome measures were re-administered, along with a posttreatment questionnaire eliciting perceptions of the treatment, after the 7-session intervention (or 2 months after randomization for those assigned to EUC) and again 2 months after the completion of the study intervention (4 months after randomization to EUC). This study was approved by the institutional review boards of Memorial Sloan Kettering Cancer Center and Fordham University and was registered with ClinicalTrials.gov (NCT01323309).
Study Interventions
MCP, a manualized psychotherapy grounded in the work of Viktor Frankl, 11 . 30 was originally developed as an 8-session group intervention 31 and was subsequently adapted to an individualized format. 12, 32 The intervention focuses on helping patients with advanced cancer develop or increase a sense of meaning in their lives, and a pilot study demonstrated its effectiveness in contrast to an attention control condition (massage therapy). 13 The current study used 2 control conditions, SP and EUC. Supportive therapy sessions also followed an established treatment manual 33 and focused on coping with advanced cancer by encouraging patients to share concerns related to their diagnosis and treatment, describe their experiences and emotions, and identify challenges. Both active treatments (IMCP and SP) were provided by a mental health clinician (psychiatrist, clinical psychologist, social worker, or doctoral student in clinical psychology) with experience in treating patients with advanced cancer. Study therapists were trained with both didactic and observational methods and completed a minimum of 2 supervised training cases before they were assigned study cases. Weekly supervision was provided by experienced clinical psychologists or psychiatrists, and all sessions were audio-recorded to assess treatment adherence. To prevent "bleed" across conditions, therapists conducted sessions in only 1 intervention. Although the 2 treatment arms were designed as weekly sessions, participants were given up to 14 weeks to complete the intervention (eg, if medical treatment needs affected their availability).
Patients assigned to EUC were provided a list of resources for mental health treatment as well as targeted referrals specific to problem areas identified on the Distress Thermometer (eg, social work, chaplaincy, and pain management). In addition, EUC patients were provided a packet of resources for coping with cancer along with a signed copy of The Human Side of Cancer, 34 a book designed to help patients cope with stressors associated with cancer and its treatment.
Adherence to Treatment Format
A random sample of sessions (n 5 108) was reviewed by a research assistant (blind to the treatment arm) to monitor treatment adherence. Ratings indicated close adherence to the treatment manual, with mean ratings for IMCP content of 0.96 (on a scale of 0-1) for IMCP sessions and 0.02 for SP sessions. Conversely, the mean ratings for SP content were 0.08 (on a scale of 0-1) for IMCP sessions and 0.97 for SP sessions. The mean ratings for therapist IMCP process behaviors were 1.71 (on a scale of 0-2) for IMCP sessions and 0.04 for SP sessions, and the mean ratings for therapist SP process behaviors were 0.30 for IMCP sessions and 1.81 for SP sessions (all P values < .001). There was no significant difference in patient ratings of the therapeutic alliance, as measured with the Working Alliance Inventory Short Form, between IMCP (mean, 69.9; SD, 12.6) and SP (mean, 67.2; SD, 11.4; t 5 1.40; P 5 .16).
Statistical Analysis
Treatment effects were analyzed with a series of mixed models. In each model, the treatment arm and the assessment time point were entered as fixed effects, and the subject was entered as a random effect. The time 3 treatment interaction served as the omnibus test of whether improvements differed for the 3 study groups, with independent contrasts comparing each intervention (IMCP and SP) against EUC and with planned comparisons contrasting the 2 active treatments against one another and a combined active treatment condition (including both IMCP and SP) against EUC. We analyzed these data twice, first including all participants who began treatment (ie, an intent-to-treat analysis) and second including only participants who attended 3 or more sessions. To control for an inflated type I error due to multiple outcome variables, we adjusted critical a values (based on 2-tailed tests) with the false discovery method. 35 
RESULTS
Group Differences in Demographic Characteristics, Attendance, and Attrition
Preliminary analyses sought to identify any group differences that might necessitate consideration as potential covariates. There were no group differences observed in any of the demographic variables. Although attrition before treatment differed significantly across the 3 conditions (14.7% for IMCP, 20.4% for SP, and 28.8% for EUC; v 2 5 6.46; df 5 2; P 5 .04; / 5 0.14), the magnitude of this difference was modest and largely due to greater attrition in the EUC arm. As noted previously, there was no difference in attrition rates when the MCP and SP arms were compared to one another, nor was there any difference in the mean number of sessions attended by IMCP and SP participants.
Efficacy of IMCP Intent-to-Treat Analyses
Analyses that included all participants who began the study (ie, provided data at the baseline assessment; n 5 321) generated a significant group 3 treatment interaction effect for each of the 3 primary outcome variables: SWB (F(2,589) 5 3.92; P 5 .02), LAP-R (F(2,598) 5 9.37; P < .0001), and MQOL (F(2,596) 5 4.53; P 5 .01). The impact of treatment on the secondary outcome variables (HAI, SAHD, HADS-A, and HADS-D) was not significant but approached significance for HADS-A (F(2,596) 5 2.87; P 5 .06). In addition, a significant main effect was observed for time (indicating improvement across the entire sample) for 4 dependent variables: SWB, HAI, HADS-A, and HADS-D. An analysis of the individual treatment arms (see Tables 2 and 3 ) revealed significantly greater improvement for IMCP patients than EUC patients in each of the 3 primary outcome variables (SWB, LAP-R, and MQOL) as well as 2 of the 4 secondary outcomes (SAHD and HADS-A); a third (HADS-D) approached significance (P 5 .07). Many of these effects remained significant even after we had controlled for a type I error with the false discovery method (see Table 2 ). There was no significant effect of SP versus EUC on any of the outcome variables. However, planned contrast analyses comparing IMCP with SP indicated significant differences in the rate of improvement for 2 variables: LAP-R (t 5 3.43; P 5 .014) and MQOL (t 5 2.38; P 5 .018). SWB also approached significance (t 5 1.88; P 5 .06).
Analysis of the Participants Who Attended 3 or More Sessions
An analysis of the participants who attended 3 or more treatment sessions (n 5 264; all EUC participants were included) generated somewhat stronger treatment effects, with a significant group 3 treatment interaction for all 3 primary outcome variables: SWB (F(2,583) 5 4.09; P 5 .02), LAP-R (F(2,592) 5 10.00; P < .0001), and MQOL (F(2,590) 5 5.05; P 5 .007). Of the 4 secondary outcome variables, only HADS-A (F(2,590) 5 3.06; P 5 .05) generated a significant treatment effect, while a fifth variable (SAHD) approached significance (F(2,589) 5 2.55; P 5 .08). When compared directly with EUC, IMCP demonstrated significantly greater improvements in 5 of the 7 dependent variables (SWB, LAP-R, MQOL, SAHD, and HADS-A), with a sixth (HADS-D) approaching significance (P 5 .07). Once again, no significant difference in improvement was observed between SP and EUC for any of the dependent variables. Post hoc contrasts demonstrated an even greater discrepancy in improvement between IMCP and SP (compared to the intent-to-treat analyses) because the improvement was greater for IMCP in each of the 3 primary outcome variables (SWB, LAP-R, and MQOL).
Notably, supplemental analyses that included sex as a possible covariate resulted in comparable findings (data available on request).
DISCUSSION
These findings add to a growing literature that supports the efficacy of MCP and provide several unique contributions. Unlike prior research, this study included a notreatment comparison arm (EUC) because distress might improve (or worsen) over time even without an intervention. In addition, we included only patients who had a moderate to high level of distress at the baseline assessment (based on a widely used screening tool, the Distress Thermometer). The results of these analyses were consistent with our prior research, demonstrating treatment effects for IMCP (small to moderate in magnitude) and little to no significant benefit from SP.
As in our previous studies, the strongest treatment effects for IMCP were observed for measures of overall quality of life, sense of meaning, and spiritual well-being. These treatment effects were somewhat stronger than those observed for SP, an active mental health intervention, but the effect size for these differences in treatment effects were small, and most comparisons of IMCP and SP were not significant. Even more modest treatment effects were observed for IMCP on the desire for hastened death, anxiety, hopelessness, and depression. These results indicate that although IMCP generated somewhat better treatment outcomes, the difference between these 2 interventions (IMCP and SP) is modest. Not surprisingly, stronger results were observed when we analyzed data from only those patients who attended at least 3 sessions. This analysis provides a less conservative estimate of The data reflect intent-to-treat analyses; bolded coefficients represent significant effects (P <.05). a Significant coefficients based on the false discovery method.
treatment effects and indicates that improvement is bolstered by more frequent attendance. Of the outcome variables studied, only depression and hopelessness failed to demonstrate significantly greater improvement in comparison with EUC because these variables improved comparably across all 3 treatment arms. This finding may be due to the relative effectiveness of other interventions in improving severe psychiatric symptoms such as depression and hopelessness, including outside sources of support or treatment (which was encouraged as part of the "enhanced" usual care). Indeed, many patients were receiving concurrent mental health interventions, and this further highlights the potential benefits of MCP as an adjuvant intervention for alleviating existential distress and improving spiritual well-being.
Although this study used a rigorous, 3-arm randomized controlled design, several methodological considerations limit the conclusiveness of these results. First, we did not control for concurrent mental health or palliative care interventions. In fact, the EUC condition explicitly facilitated identifying outside sources of support. Some participants (in all 3 arms) were also on concomitant psychotropic medications (whether prescribed for psychiatric symptoms or other reasons, eg, sedation or neuropathic pain). Controlling for the countless variations in psychotropic medications (including the type of medication, reason prescribed, and dose) was simply not feasible, and this may have hindered our assessment of the relative effectiveness of IMCP. Similarly, although we opted to set a minimum threshold of distress for entry into the study, it is not clear whether this helped or hindered our analyses because it likely reduced the range of distress observed in the sample. This decision was made to more accurately assess the utility of IMCP in alleviating distress (because improvement is harder to establish in patients with low levels of distress), but the extent to which this methodological decision affected our findings is unknown. Disappointment in being assigned to EUC may also have affected our study findings (and led to the slightly higher attrition rate among EUC participants). Finally, the generalizability of these results is limited by the overrepresentation of women in our sample. Although post hoc analyses indicated no difference in treatment effects between men and women, further research examining this possible source of bias is warranted. Despite these study limitations, our results provide further evidence that MCP is an effective intervention for improving quality of life and spiritual well-being and reducing psychological distress. This intervention targets the challenging domains of existential and spiritual despair, which many clinicians feel ill prepared to address. Because of the importance of spiritual well-being and sense of meaning among patients confronting a terminal illness, the availability of a manualized, empirically supported intervention such as IMCP has tremendous potential for improving patient quality of life during the final months of life. Moreover, although this intervention was designed for patients with advanced cancer, the focus on (and utility for) enhancing meaning and quality of life may have broad applicability across a range of illnesses and conditions in which physical and psychological functioning is adversely affected.
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